Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 21, Issue 4, Pages 515-522Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2012.660250
Keywords
oxazolidinone; skin and skin structure infections; Staphylococcus aureus; tedizolid
Categories
Ask authors/readers for more resources
Introduction: Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid. Areas covered: This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics/pharmacodynamics, clinical efficacy and safety are all addressed. Expert opinion: Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available